Physician profile
Mukesh Kumar
NPI 1144566712
$918.14
in general payments reported to CMS, 2019-2025
11 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2022: $184 · 2024: $45.11 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $227.16 | 2019 | |
| Genzyme Corporation | $185.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $111.62 | 2022 | |
| Scpharmaceuticals INC. | $110.00 | 2025 | |
| Intuitive Surgical, INC. | $72.64 | 2022 | |
| Merck Sharp & Dohme LLC | $70.97 | 2025 | Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.84 | 2025 | Xifaxan |
| Recor Medical INC | $25.79 | 2024 | Paradise Renal Denervation System |
| Amgen INC. | $19.32 | 2024 | |
| Gilead Sciences, INC. | $16.04 | 2025 | Veklury |
| Mallinckrodt Hospital Products INC. | $14.76 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.